KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables (2016 - 2025)

Historic Receivables for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $905000.0.

  • Arbutus Biopharma's Receivables fell 4371.89% to $905000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $905000.0, marking a year-over-year decrease of 4371.89%. This contributed to the annual value of $2.4 million for FY2024, which is 3564.19% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Receivables of $905000.0 as of Q3 2025, which was down 4371.89% from $1.0 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Receivables high stood at $2.7 million for Q1 2023, and its period low was $899000.0 during Q4 2021.
  • Moreover, its 5-year median value for Receivables was $1.7 million (2021), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Arbutus Biopharma's Receivables soared by 10289.41% in 2023, and later crashed by 4474.05% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Receivables (Quarter) stood at $899000.0 in 2021, then soared by 50.39% to $1.4 million in 2022, then surged by 31.36% to $1.8 million in 2023, then skyrocketed by 35.64% to $2.4 million in 2024, then tumbled by 62.43% to $905000.0 in 2025.
  • Its Receivables stands at $905000.0 for Q3 2025, versus $1.0 million for Q2 2025 and $1.2 million for Q1 2025.